JP2010518115A5 - - Google Patents

Info

Publication number

JP2010518115A5

JP2010518115A5 JP2009549247A JP2009549247A JP2010518115A5 JP 2010518115 A5 JP2010518115 A5 JP 2010518115A5 JP 2009549247 A JP2009549247 A JP 2009549247A JP 2009549247 A JP2009549247 A JP 2009549247A JP 2010518115 A5 JP2010518115 A5 JP 2010518115A5

Authority

JP

Japan

Prior art keywords

cancer

antibody

seq

hvr

group

Prior art date

2008-02-08

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 241000124008 Mammalia Species 0.000 claims description 15
• 206010028980 Neoplasm Diseases 0.000 claims description 15
• 201000011510 cancer Diseases 0.000 claims description 15
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
• 210000001519 tissue Anatomy 0.000 claims description 15
• 229940127089 cytotoxic agent Drugs 0.000 claims description 13
• 206010064930 age-related macular degeneration Diseases 0.000 claims description 12
• 230000033115 angiogenesis Effects 0.000 claims description 12
• 208000002780 macular degeneration Diseases 0.000 claims description 12
• 239000002254 cytotoxic agent Substances 0.000 claims description 10
• 231100000599 cytotoxic agent Toxicity 0.000 claims description 10
• 201000010099 disease Diseases 0.000 claims description 9
• 239000003795 chemical substances by application Substances 0.000 claims description 8
• 210000004027 cell Anatomy 0.000 claims description 7
• 239000003814 drug Substances 0.000 claims description 7
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
• 201000001320 Atherosclerosis Diseases 0.000 claims description 6
• 206010009944 Colon cancer Diseases 0.000 claims description 6
• 206010012689 Diabetic retinopathy Diseases 0.000 claims description 6
• 208000010412 Glaucoma Diseases 0.000 claims description 6
• 208000008839 Kidney Neoplasms Diseases 0.000 claims description 6
• 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims description 6
• 201000004681 Psoriasis Diseases 0.000 claims description 6
• 206010038389 Renal cancer Diseases 0.000 claims description 6
• 206010038934 Retinopathy proliferative Diseases 0.000 claims description 6
• 239000002246 antineoplastic agent Substances 0.000 claims description 6
• 208000037976 chronic inflammation Diseases 0.000 claims description 6
• 230000006020 chronic inflammation Effects 0.000 claims description 6
• 208000035475 disorder Diseases 0.000 claims description 6
• 201000011066 hemangioma Diseases 0.000 claims description 6
• 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 6
• 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 6
• 201000010982 kidney cancer Diseases 0.000 claims description 6
• 201000007270 liver cancer Diseases 0.000 claims description 6
• 208000014018 liver neoplasm Diseases 0.000 claims description 6
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
• MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 claims description 4
• IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 claims description 4
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 4
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 4
• 108010093470 monomethyl auristatin E Proteins 0.000 claims description 4
• 108010059074 monomethylauristatin F Proteins 0.000 claims description 4
• 201000003142 neovascular glaucoma Diseases 0.000 claims description 4
• 206010061424 Anal cancer Diseases 0.000 claims description 3
• 201000003076 Angiosarcoma Diseases 0.000 claims description 3
• 208000007860 Anus Neoplasms Diseases 0.000 claims description 3
• 208000003950 B-cell lymphoma Diseases 0.000 claims description 3
• 206010005003 Bladder cancer Diseases 0.000 claims description 3
• 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
• 206010006187 Breast cancer Diseases 0.000 claims description 3
• 208000026310 Breast neoplasm Diseases 0.000 claims description 3
• 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
• 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 3
• 206010014733 Endometrial cancer Diseases 0.000 claims description 3
• 206010014759 Endometrial neoplasm Diseases 0.000 claims description 3
• 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 3
• 208000001258 Hemangiosarcoma Diseases 0.000 claims description 3
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
• 208000032271 Malignant tumor of penis Diseases 0.000 claims description 3
• 206010027476 Metastases Diseases 0.000 claims description 3
• 208000034578 Multiple myelomas Diseases 0.000 claims description 3
• 206010033128 Ovarian cancer Diseases 0.000 claims description 3
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
• 208000002471 Penile Neoplasms Diseases 0.000 claims description 3
• 206010034299 Penile cancer Diseases 0.000 claims description 3
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
• 206010060862 Prostate cancer Diseases 0.000 claims description 3
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
• 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
• 208000005718 Stomach Neoplasms Diseases 0.000 claims description 3
• 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
• 208000006593 Urologic Neoplasms Diseases 0.000 claims description 3
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
• 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
• 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 3
• 229940034982 antineoplastic agent Drugs 0.000 claims description 3
• 201000011165 anus cancer Diseases 0.000 claims description 3
• 201000010881 cervical cancer Diseases 0.000 claims description 3
• 208000029742 colonic neoplasm Diseases 0.000 claims description 3
• 206010017758 gastric cancer Diseases 0.000 claims description 3
• 208000005017 glioblastoma Diseases 0.000 claims description 3
• 201000010536 head and neck cancer Diseases 0.000 claims description 3
• 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
• 238000011503 in vivo imaging Methods 0.000 claims description 3
• 230000002401 inhibitory effect Effects 0.000 claims description 3
• 201000005202 lung cancer Diseases 0.000 claims description 3
• 208000020816 lung neoplasm Diseases 0.000 claims description 3
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
• 201000001441 melanoma Diseases 0.000 claims description 3
• ANZJBCHSOXCCRQ-FKUXLPTCSA-N mertansine Chemical group CO[C@@H]([C@@]1(O)C[C@H](OC(=O)N1)[C@@H](C)[C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(=O)CCS)CC(=O)N1C)\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 ANZJBCHSOXCCRQ-FKUXLPTCSA-N 0.000 claims description 3
• 201000008968 osteosarcoma Diseases 0.000 claims description 3
• 201000002528 pancreatic cancer Diseases 0.000 claims description 3
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
• 201000002628 peritoneum cancer Diseases 0.000 claims description 3
• 206010038038 rectal cancer Diseases 0.000 claims description 3
• 201000001275 rectum cancer Diseases 0.000 claims description 3
• 206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
• 201000011549 stomach cancer Diseases 0.000 claims description 3
• 201000002510 thyroid cancer Diseases 0.000 claims description 3
• 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
• 206010046766 uterine cancer Diseases 0.000 claims description 3
• 201000005102 vulva cancer Diseases 0.000 claims description 3
• NKIJBSVPDYIEAT-UHFFFAOYSA-N 1,4,7,10-tetrazacyclododec-10-ene Chemical compound C1CNCCN=CCNCCN1 NKIJBSVPDYIEAT-UHFFFAOYSA-N 0.000 claims description 2
• WDLRUFUQRNWCPK-UHFFFAOYSA-N Tetraxetan Chemical compound OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)CCN(CC(O)=O)CC1 WDLRUFUQRNWCPK-UHFFFAOYSA-N 0.000 claims description 2
• 125000000539 amino acid group Chemical group 0.000 claims description 2
• 239000011616 biotin Substances 0.000 claims description 2
• 229960002685 biotin Drugs 0.000 claims description 2
• 235000020958 biotin Nutrition 0.000 claims description 2
• 239000002738 chelating agent Substances 0.000 claims description 2
• 238000012217 deletion Methods 0.000 claims description 2
• 230000037430 deletion Effects 0.000 claims description 2
• 239000000839 emulsion Substances 0.000 claims description 2
• 239000007850 fluorescent dye Substances 0.000 claims description 2
• 238000003780 insertion Methods 0.000 claims description 2
• 230000037431 insertion Effects 0.000 claims description 2
• 239000002923 metal particle Substances 0.000 claims description 2
• 239000002105 nanoparticle Substances 0.000 claims description 2
• -1 radionuclide Substances 0.000 claims description 2
• 238000006467 substitution reaction Methods 0.000 claims description 2
• TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 claims description 2
• 239000000203 mixture Substances 0.000 claims 15
• 230000002491 angiogenic effect Effects 0.000 claims 2
• 238000004519 manufacturing process Methods 0.000 claims 2
• 238000000034 method Methods 0.000 description 14
• 101150050515 Robo4 gene Proteins 0.000 description 5
• 101100145112 Mus musculus Robo4 gene Proteins 0.000 description 4
• 241000288906 Primates Species 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 238000003745 diagnosis Methods 0.000 description 1
• 229940079593 drug Drugs 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1